Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL2240490 | 1.00 | CA2 (0.45) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL28271598 | 0.97 | CA2 (0.43) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL1932986 | 0.90 | CA2 (0.43) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL2290380 | 0.89 | ALDH1A1 (0.45) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL28243370 | 0.89 | ALDH1A1 (0.45) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL27964313 | 0.89 | ALDH1A1 (0.45) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL9460589 | 0.89 | ALDH1A1 (0.45) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL295 | 0.89 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL39465 | 0.89 | ALDH1A1 (0.50) | CA2CA1ALDH1A1L3MBTL1CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL3950101 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | claimed |
| US-20110186828-A1 | Blue light-Emitting Material | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| EP-1155064-A1 | ADDITION OF TREATMENT AGENTS TO SOLID PHASE POLYMERIZATION PROCESSES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-11-21 | — | — | EP | claimed |
| US-6180756-B1 | SOLID PHASE CONDENSATION POLYMERIZATION PROCESS | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-01-30 | — | — | US | claimed |
| WO-2000049065-A1 | ADDITION OF TREATMENT AGENTS TO SOLID PHASE POLYMERIZATION PROCESSES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-08-24 | — | — | WO | claimed |
| US-5089192-A | Casted from solution containing acid | IONICS, INCORPORATED (US) | 1992-02-18 | — | — | US | claimed |
| US-4312986-A | REACTION OF CORRESPONDING ESTER OR CARBAMATE WITH MERCAPTO COMPOUND | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-01-26 | — | — | US | claimed |
| CN-115677689-B | Polysubstituted benzene PD-L1 inhibitor, composition and application thereof | 杭州和正医药有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118647309-A | Molecular sensors, methods and kits for detecting and quantifying carbon dioxide | 苏黎世联邦理工学院 | 2024-09-13 | — | — | CN | disclosed |
| CN-118496203-A | Quinoxaline compound and medical application thereof | 苏州隆博泰药业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118496225-A | Azaquinolinone compounds and medical application thereof | 苏州隆博泰药业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-115232125-B | Polysubstituted benzene immunomodulatory compounds, composition and application thereof | 杭州和正医药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114573586-B | Polycyclic compound for inhibiting Bruton tyrosine kinase activity, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-6180756-B1 | SOLID PHASE CONDENSATION POLYMERIZATION PROCESS | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| CN-1265645-A | Urokinase inhibitors | ABBOTT LAB (US) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000049065-A1 | ADDITION OF TREATMENT AGENTS TO SOLID PHASE POLYMERIZATION PROCESSES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| CN-1169986-A | 2.9-diamino-and 2-amino-8-carbamoyl-4-hydroxy-aldanoic acid amide derivatives | CIBA GEIGY AG (CH) | 1998-01-14 | — | — | CN | disclosed |
| US-5294623-A | (Benzhydryloxyethylpiperidyl) aliphatic acid derivatives and their use in the treatment of allergies and asthma | SANKYO COMPANY, LIMITED (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5177245-A | Alkylation | EASTMAN KODAK COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0330939-A2 | Acrylic acid morpholides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110186828-A1 | Blue light-Emitting Material | CRY1, CRY2, MAP1LC3A | F2 2858/4885CA2 4789/4885CA1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.